TD Cowen analyst Charles Rhyee lowered the firm’s price target on Charles River (CRL) to $197 from $205 and keeps a Buy rating on the shares. The firm said the company’s strategic review update suggests a full Mfr. sale is unlikely, and the reality is DSA revenue growth will be challenged in 2026, with the base case being revenue growth down.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRL:
- Buy Rating for Charles River Labs: Potential Upside Amid Dynamic Environment and Favorable Trends
- Charles River price target raised to $165 from $160 at JPMorgan
- Charles River upgraded to Outperform from Neutral at Baird
- Charles River Laboratories Reports Q3 2025 Earnings
- Charles River Labs Earnings Call: Mixed Sentiments and Strategic Moves